levonorgestrel-butanoate has been researched along with testosterone-undecanoate* in 2 studies
1 review(s) available for levonorgestrel-butanoate and testosterone-undecanoate
| Article | Year |
|---|---|
Perspectives of contraceptive choices for men.
Apart from condoms and vasectomy, which have several limitations of their own, no other methods of contraception are available to men. Various chemical, hormonal, vas based and herbal contraceptives have been examined and few of them have reached the stage of clinical testing. Promising leads have been obtained from testosterone buciclate/undecanoate, alone or in combination with levonorgestrel butanoate or cyproterone acetate, RISUG, an injectable intravasal contraceptive and a few herbal products, particularly the seed products of Carica papaya. It is feasible that an ideal male contraceptive, that meets out all the essential criteria will be made available to the community in the near future. Topics: Carica; Clinical Trials as Topic; Contraception; Contraceptive Agents; Contraceptive Agents, Male; Cyproterone Acetate; Dimethyl Sulfoxide; Hormones; Humans; Male; Maleates; Norgestrel; Polyesters; Polystyrenes; Styrenes; Testosterone; Vasectomy | 2005 |
1 other study(ies) available for levonorgestrel-butanoate and testosterone-undecanoate
| Article | Year |
|---|---|
Male contraceptive research steps back into spotlight.
The goal of male hormonal contraception is to block spermatogenesis by suppressing the secretion of pituitary gonadotropins. Prospects are good for the development of such a male contraceptive, with at least one hormonal contraceptive for men potentially available within 5-7 years. Finding an acceptable, reversible, and preferably long-lasting hormonal contraceptive for men is a top priority of the World Health Organization (WHO). Considerable evidence suggests that an androgen, with or without a progestogen, can provide effective contraception and is well tolerated. Schering and Organon are planning to collaborate with WHO in developing hormonal contraception for men. Fred Wu of the University of Manchester, UK, will soon begin a trial comparing the effectiveness of new injectable testosterone undecanoate and testosterone buciclate formulations, with or without synthetic progestogens. Topics: Humans; Injections, Intramuscular; Male; Norgestrel; Research; Spermatogenesis-Blocking Agents; Testosterone; Testosterone Congeners; World Health Organization | 1999 |